Polycystic Kidney Disease – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Polycystic Kidney Disease – Pipeline Review, H1 2017’, provides an overview of the Polycystic Kidney Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease

The report reviews pipeline therapeutics for Polycystic Kidney Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Polycystic Kidney Disease therapeutics and enlists all their major and minor projects

The report assesses Polycystic Kidney Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Angion Biomedica Corp

Aptevo Therapeutics Inc

Conatus Pharmaceuticals Inc

DiscoveryBiomed Inc

Endocyte Inc

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Metabolic Solutions Development Company LLC

Mironid Ltd

NovaTarg Therapeutics Inc

Otsuka Holdings Co Ltd

Q BioMed Inc

Regulus Therapeutics Inc

XORTX Pharma Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Kidney Disease - Overview

Polycystic Kidney Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Kidney Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Kidney Disease - Companies Involved in Therapeutics Development

3SBio Inc

Angion Biomedica Corp

Aptevo Therapeutics Inc

Conatus Pharmaceuticals Inc

DiscoveryBiomed Inc

Endocyte Inc

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Metabolic Solutions Development Company LLC

Mironid Ltd

NovaTarg Therapeutics Inc

Otsuka Holdings Co Ltd

Q BioMed Inc

Regulus Therapeutics Inc

XORTX Pharma Corp

Polycystic Kidney Disease - Drug Profiles

(sodium ascorbate + menadione sodium bisulfite) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBM-43H11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DJ-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Cystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-0371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-8050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

menadione sodium bisulfite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSDC-0160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxypurinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrimethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGLS-4326 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE4 for Kidney Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STA-2842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesevatinib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNFR x TWEAKR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolvaptan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Kidney Disease - Dormant Projects

Polycystic Kidney Disease - Discontinued Products

Polycystic Kidney Disease - Product Development Milestones

Featured News & Press Releases

Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan

Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD

Dec 06, 2016: Regulus Announces Update on RGLS4326

Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016

Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease

Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015

May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease

Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease

Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease

Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide

Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease

Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease

May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease

Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Polycystic Kidney Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Polycystic Kidney Disease – Pipeline by 3SBio Inc, H1 2017

Polycystic Kidney Disease – Pipeline by Angion Biomedica Corp, H1 2017

Polycystic Kidney Disease – Pipeline by Aptevo Therapeutics Inc, H1 2017

Polycystic Kidney Disease – Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Polycystic Kidney Disease – Pipeline by DiscoveryBiomed Inc, H1 2017

Polycystic Kidney Disease – Pipeline by Endocyte Inc, H1 2017

Polycystic Kidney Disease – Pipeline by IC-MedTech Inc, H1 2017

Polycystic Kidney Disease – Pipeline by Ipsen SA, H1 2017

Polycystic Kidney Disease – Pipeline by Kadmon Corp LLC, H1 2017

Polycystic Kidney Disease – Pipeline by ManRos Therapeutics, H1 2017

Polycystic Kidney Disease – Pipeline by Metabolic Solutions Development Company LLC, H1 2017

Polycystic Kidney Disease – Pipeline by Mironid Ltd, H1 2017

Polycystic Kidney Disease – Pipeline by NovaTarg Therapeutics Inc, H1 2017

Polycystic Kidney Disease – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Polycystic Kidney Disease – Pipeline by Q BioMed Inc, H1 2017

Polycystic Kidney Disease – Pipeline by Regulus Therapeutics Inc, H1 2017

Polycystic Kidney Disease – Pipeline by XORTX Pharma Corp, H1 2017

Polycystic Kidney Disease – Dormant Projects, H1 2017

Polycystic Kidney Disease – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Polycystic Kidney Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports